NCT01385839

Brief Summary

The purpose of this study is to look at the safety, as well as the efficacy of hair transplantation compared with irritation with hypodermic needles in the treatment of subjects with refractory alopecia areata. With this study, the investigators hope to demonstrate that trauma is just as effective as hair transplant in the treatment of recalcitrant alopecia areata of the scalp.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2009

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

June 28, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 30, 2011

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

December 22, 2016

Status Verified

December 1, 2016

Enrollment Period

2.6 years

First QC Date

June 28, 2011

Last Update Submit

December 20, 2016

Conditions

Keywords

AlopeciaHair transplantationNeedle irritationMedical needling

Outcome Measures

Primary Outcomes (5)

  • Change in follicular growth

    The study will require 5 study visits: Day 0, Day 1, Week 2, Week 24, and Week 36.

    day 0

  • Change in follicular growth

    The study will require 5 study visits: Day 0, Day 1, Week 2, Week 24, and Week 36.

    day 1

  • Change in follicular growth

    The study will require 5 study visits: Day 0, Day 1, Week 2, Week 24, and Week 36.

    2 weeks

  • Change in follicular growth

    The study will require 5 study visits: Day 0, Day 1, Week 2, Week 24, and Week 36.

    24 weeks

  • Change in follicular growth

    The study will require 5 study visits: Day 0, Day 1, Week 2, Week 24, and Week 36.

    36 weeks

Study Arms (1)

alopecia areata

EXPERIMENTAL

pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle

Procedure: Hair transplantationProcedure: Hypodermic needle irritation

Interventions

Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.

alopecia areata

In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.

alopecia areata

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject must have recalcitrant, quiescent, alopecia areata, non-responsive to treatment, for at least 6 months.
  • Subject must have one patch of alopecia areata greater than 5 cm diameter, of two patches of alopecia areata, each greater than 2.5 cm diameter.

You may not qualify if:

  • Subjects with active, progressive, alopecia areata.
  • Subjects who are actively experiencing significant spontaneous regrowth of terminal hair.
  • Subjects with autoimmune deficiency.
  • Subjects with a medical condition contraindicating use of anesthesia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Icahn School of Medicine at Mount Sinai, Department of Dermatology Clinical Trials Center

New York, New York, 10029, United States

Location

Related Publications (5)

  • Civas E, Aksoy B, Aksoy HM, Eski M, Yucel K. Hair transplantation for therapy-resistant alopecia areata of the eyebrows: is it the right choice? J Dermatol. 2010 Sep;37(9):823-6. doi: 10.1111/j.1346-8138.2010.00872.x.

    PMID: 20883369BACKGROUND
  • Barankin B, Taher M, Wasel N. Successful hair transplant of eyebrow alopecia areata. J Cutan Med Surg. 2005 Aug;9(4):162-4. doi: 10.1007/s10227-005-0136-x.

    PMID: 16502201BACKGROUND
  • Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004413. doi: 10.1002/14651858.CD004413.pub2.

    PMID: 18425901BACKGROUND
  • Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg. 2009 Mar;28(1):15-8. doi: 10.1016/j.sder.2008.12.002.

    PMID: 19341938BACKGROUND
  • Lee JW, Yoo KH, Kim BJ, Kim MN. Photodynamic therapy with methyl 5-aminolevulinate acid combined with microneedle treatment in patients with extensive alopecia areata. Clin Exp Dermatol. 2010 Jul;35(5):548-9. doi: 10.1111/j.1365-2230.2009.03695.x. Epub 2009 Nov 3. No abstract available.

    PMID: 19886963BACKGROUND

MeSH Terms

Conditions

Alopecia AreataAlopecia

Condition Hierarchy (Ancestors)

HypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Robin Unger, MD

    Icahn School of Medicine at Mount Sinai

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2011

First Posted

June 30, 2011

Study Start

October 1, 2009

Primary Completion

May 1, 2012

Study Completion

May 1, 2012

Last Updated

December 22, 2016

Record last verified: 2016-12

Locations